piwik-script

English Intern
Lehrstuhl für klinische Epidemiologie und Biometrie

UNITI

Unification of treatments and Interventions for Tinnitus patients

Koordinator UNITI :

Winfried Schlee, Universität Regensburg, Deutschland

Koordination des WP 4 (Harmonisierung technischer Lösungen):

Prof. Rüdiger PryssCarsten Vogel

Founder:

European Union Research and Innovation programme Horizon 2020

Status:

Dauer 39 Monate, Start Datum 01 Jan 2020, grant number 848261

 

Beschreibung

Tinnitus is the perception of a phantom sound and the patient’s reaction to it. Tinnitus remains a scientific and clinical enigma of iTinnitus is the perception of a phantom sound and the patient’s reaction to it. Although much progress has been made, tinnitus remains a scientific and clinical enigma of high prevalence and high economic burden. It affects more than 10% of the general population, whereas 1% of the population considers tinnitus their major health issue. Recent cohort studies show that tinnitus prevalence tends to increase over time and with older age. Assuming that there is no cure to be found, the prevalence estimates in Europe would double by 2050. A large variety of patient characteristics - including genotyping, aetiology, and phenotyping - are poorly understood, because integrated systems approaches are still missing to correlate patient`s characteristics to predict responses to combinatorial therapies.

Although genetic causes of tinnitus have been neglected for decades, recent findings of genetic analysis in specific subgroups (gender and phenotype) have highlighted that bilateral tinnitus in men reached a heritability of 0.68. This heritability is close to autism, schizophrenia and Attention Deficit Hyperactive Disorder (ADHD). There is no current consensus on tinnitus treatment. UNITI’s overall aim is to deliver a predictive computational model based on existing and longitudinal data attempting to address the question which treatment approach is optimal for a specific patient based on specific parameters. Clinical, epidemiological, medical, genetic and audiological data, including signals reflecting ear-brain communication, will be analysed from existing databases. Predictive factors for different patient groups will be extracted and their prognostic relevance will be tested in a randomized controlled trial (RCT) in which different groups of patients will undergo a combination of therapies targeting the auditory and central nervous systems.

Arbeitspakete

Arbeitspaket Inhalt Verantwortung
WP1 Ethics University of Regensburg (UHREG)
WP2 Project Management University of Regensburg (REG)
WP3 Analysis of existing data University of Magdeburg (MAG)
WP4 Harmonization of technical solutions Julius-Maximilians-Universität Würzburg (JMU)
WP5 Intelligent data analysis ICCS
WP6 Genetics GRA
WP7 Randomized Clinical Trial University of Regensburg (REG)
WP8 Dissemination, Communication and Exploitation VIL

 

Übersicht

Partner

Nr Name Abkürzung Land Projekteintrittsmonat Projektabschlussmonat

1.

KLINIKUM DER UNIVERSITAET REGENSBURG UHREG

Deutschland

1 39

2.

KATHOLIEKE UNIVERSITEIT LEUVEN KUL Belgien 1 39

3.

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON UOA Griechenland 1 39

4.

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

CHA

Deutschland 1 39

5.

SERVICIO ANDALUZ DE SALUD

GRA

Spanien 1 39

6.

KAROLINSKA INSTITUTET

KI

Schweden 1 39

7.

OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG

MAG

Deutschland 1 39

8.

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS- UNIVERSITAET

JMU

Deutschland 1 39

9.

INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS

ICCS

Griechenland 1 39

10.

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI MIL Italien 1 39

11.

VILABS (CY) LTD VIL Zypern 1 39

12.

SPHYNX TECHNOLOGY SOLUTIONS AG

SPX

Schweiz 1 39

13.

ZEINCRO EGESZSEGUGYI SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG

ZEI Ungarn 1 39